In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision related to COVID-19 vaccines, and Eli Lilly announces plans for a $3 billion manufacturing facility in Pennsylvania.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision related to COVID-19 vaccines, and Eli Lilly announces plans for a $3 billion manufacturing facility in Pennsylvania.
The FDA has launched a new PreCheck pilot program designed to streamline regulatory engagement for domestic drug manufacturers. The initiative is intended to identify potential compliance issues earlier in the manufacturing lifecycle and support efforts to strengthen US-based production capacity.
In a separate development, an Advisory Committee on Immunization Practices member has claimed that the FDA commissioner intervened to halt a decision related to removing certain COVID-19 vaccines from the market. The allegation highlights ongoing tensions around vaccine oversight, regulatory independence, and post-pandemic policy decision-making.
Finally, Eli Lilly has announced plans to invest $3 billion in a new manufacturing facility in Pennsylvania. The site will support large-scale production and reflects the company’s broader strategy to expand domestic manufacturing infrastructure amid growing policy and supply chain pressures.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
